Company Overview
Vivani Medical, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the development of miniaturized and subdermal drug implants designed to treat chronic diseases. This operational focus places the entity squarely within the Healthcare sector and the Biotechnology industry, where the primary objective involves translating novel medical technologies into therapeutic solutions without relying on traditional oral or injectable medication delivery systems. The company currently maintains a market capitalization of $86.34M and employs 37 individuals to execute its research and development initiatives. Given that the company reports no annual revenue and possesses a market cap of $86.34M, these figures indicate that Vivani Medical is an early-stage venture with a valuation driven primarily by the potential future commercialization of its NanoPortal implant technology rather than current cash flow generation or established sales volume.
Financial Health
Vivani Medical, Inc. reported a Net Income of $-26,026,000 and an EBITDA of $-26,808,000 over the trailing twelve months, while the company's Revenue is listed as N/A. The substantial gap between the reported Net Income and the negative EBITDA suggests a cost structure heavily burdened by non-operating expenses or significant tax adjustments relative to the core operational losses inherent in clinical-stage development. The company generated a Free Cash Flow of $-15,616,750, which indicates a complete lack of financial flexibility to fund operations without external capital injections such as equity offerings or debt financing. Analysis of the margin profile reveals a Gross Margin of 0.0%, an Operating Margin of 0.0%, and a Profit Margin of 0.0%, all of which signify that the company has not yet achieved profitability and is burning cash to advance its clinical pipeline. On the balance sheet, the company holds $2.63M in cash against $18.29M in debt, resulting in a Debt to Equity ratio of 1397.48, which characterizes the financial position as highly leveraged and dependent on future financing events. The Current Ratio stands at 0.61, indicating that current liabilities exceed current assets and signaling potential short-term liquidity constraints if cash inflows do not materialize rapidly. Furthermore, the Return on Equity is -265.0% and the Return on Assets is -50.1%, metrics that reveal management is currently destroying value per share and utilizing assets inefficiently due to the lack of revenue generation and significant accumulated losses.
Valuation Assessment
The trailing twelve-month P/E Ratio is N/A because the company has not generated positive earnings, while the Forward P/E is listed as -2.91, implying that future earnings projections are also negative or that the metric is not applicable for valuation purposes based on expected earnings trajectory. The Price to Book ratio is 48.57, indicating that the market values the company at a massive premium over its net asset value, a common characteristic for clinical-stage biotech firms where the asset base is understated by book accounting standards that do not fully capture intellectual property potential. The Price to Sales ratio is N/A due to the absence of revenue, and the EV/EBITDA is -3.52, suggesting that enterprise value multiples are currently distorted by negative earnings and the high debt load relative to the market cap of $86.34M. The stock has traded between a 52-Week High of $1.92 and a 52-Week Low of $0.91, placing the current valuation within a range that reflects high volatility typical of small-cap biotechnology stocks. With a Beta of 3.36, the stock exhibits extreme price volatility, moving with significantly higher intensity than the broader market, which means price swings will be amplified during periods of sector rotation or market stress.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, reflecting the company's status as a pre-revenue entity where historical growth rates are not applicable or calculable. Since the company is not yet generating commercial sales, it is impossible to determine whether earnings are growing faster or slower than revenue, as both metrics are currently defined by the progression of clinical trials rather than market expansion. Vivani Medical, Inc. does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning the company retains all resources to fund its research and development efforts rather than distributing income to shareholders. The overall growth and income profile is defined entirely by the binary success of its clinical programs and the ability to secure capital, with no current contribution to shareholder income through dividends or capital appreciation derived from earnings growth.